COMMUNIQUÉS West-GlobeNewswire

Olivaro Drops Publishes 2026 Supplement Facts and Serving Information for Its Liquid Dietary Supplement
28/09/2026
Chromium Picolinate, Maca, Gymnema, and a 200 mg Proprietary Blend: Olivaro's Full Ingredient List and Serving Directions Explained Lakeland, FL, Sept. 28, 2026 (GLOBE NEWSWIRE) -- These statements have not been [...]
Egetis Therapeutics Announces U.S. FDA Approval of EMCITATE® (tiratricol) for Patients with MCT8 Deficiency
28/09/2026
First and only FDA-approved treatment of peripheral thyrotoxicosis in adults and pediatric patients with monocarboxylate transporter 8 (MCT8) deficiency in the United States Egetis launches Egetis RareLink™, the [...]
Currus Biologics announces FDA IND clearance for Phase 1 trial of CUR-001 in mesothelin-positive advanced refractory solid tumours
29/09/2026
The first clinical programme from Currus’ BEAT platform, designed to overcome the barriers that have limited CAR T-cell therapy in solid tumours CUR-001 combines CURB-001, Currus’ BEAT bispecific antibody, with CURT-001 [...]
Mint Ops becomes an official reseller of the Coro cybersecurity platform, bringing single-platform security to Canadian dental practices
29/09/2026
The dental business services company secured its own infrastructure with Coro before offering it to clients - and is publishing its pricing, per user, on day one. Winnipeg, MANITOBA, Sept. 28, 2026 (GLOBE NEWSWIRE) -- [...]
HUTCHMED Announces Submission of US NDA for ORPATHYS® plus TAGRISSO® in MET-Driven EGFR-Mutated Lung Cancer
29/09/2026
— Filing seeks approval for a biomarker-directed, all-oral treatment option for patients whose tumors have MET overexpression or amplification, after progression on an EGFR-TKI therapy — — Application supported by [...]
Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences
29/09/2026
SAN DIEGO, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Belite Bio , Inc (NASDAQ: BLTE) (“Belite Bio ® ” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative [...]
EvergreenHealth receives transformative $100M gift from Dean Weidner
28/09/2026
The gift enables EvergreenHealth to accelerate long-term planning for expanded access and increased capacity to deliver high-quality care to the community KIRKLAND, Wash., Sept. 28, 2026 (GLOBE NEWSWIRE) -- [...]
Fetal surgeon Payam Saadai, MD, to join Rady Children’s Health Orange County
28/09/2026
Recruitment will advance specialized fetal care for families across Southern California ORANGE, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Rady Children’s Health Orange County (Rady Children’s), formerly CHOC, announced [...]
Une nouvelle analyse modélisée renforce le potentiel de TECVAYLI®▼ (teclistamab) associé au daratumumab pour redéfinir les perspectives de survie à long terme dans le myélome multiple en rechute/réfractaire dans les premières lignes de traitement
28/09/2026
Selon l’analyse, environ 87 pour cent des patients traités par TECVAYLI ® ▼ associé au daratumumab dès la deuxième ligne pourraient présenter un risque de mortalité comparable à celui de la population générale 1 Une [...]
GENFIT : Résultats financiers du premier semestre 2026 et point sur les activités de la Société
28/09/2026
Résultats financiers marquants : Trésorerie et équivalents de trésorerie s’élevant à 113,8 millions d’euros au 30 juin 2026; devant permettre à la Société de financer ses activités au-delà de la fin de l’année 2028 [...]
GENFIT Reports First-Half 2026 Financial Results and Provides Corporate Update
28/09/2026
Financial Highlights Cash and cash equivalents totaled €113.8 million as of June 30, 2026; expected to fund the Company beyond the end of 2028 €21.1 million in revenues as of June 30, 2026, including €21.0 million in [...]
ProText Mobility Issues Significant Inter-Quarter Shareholder Update: ABSA Confirms Inaugural Digital-Asset Custody Pilot as TXTM Advances Global RWA and Uplist Strategy
28/09/2026
Company highlights a significant institutional milestone, advancing its intended regulated-exchange uplist through institutional custody, deployed SVLT infrastructure, proprietary nanotechnology, international real- [...]
Interra Health Named Quarterfinalist in the 2026 Digital Health & AI Awards
28/09/2026
BOSTON, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Interra Health , which delivers the first patient-centric medication prescribing experience, announced today that it has been named a Quarterfinalist in the 2026 Digital Health [...]
Teva Continues Biosimilar Momentum with U.S. FDA Approval of DEGEVMA™ (denosumab-adet), a Biosimilar to Xgeva® (denosumab)
28/09/2026
DEGEVMA™ is now FDA-approved across all indications of the reference product, Xgeva ® (denosumab), to help prevent bone complications in adults with advanced cancer that has spread to the bone, for the treatment of [...]
Zealand Pharma - Transactions related to share buy-back program (week 39, 2026)
28/09/2026
Company announcement No. 50 / 2026 Zealand Pharma - Transactions related to share buy-back program (week 39, 2026) Copenhagen, Denmark, September 28, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq [...]
PerfectServe Doubles Down on Innovation to Help Health Systems Define, Measure, and Achieve Operational Excellence
28/09/2026
Building on 30 years of healthcare operational experience, PerfectServe is investing in technologies that deliver immediate value while creating the foundation for connected operational intelligence. Summary Defining [...]
Advance OC’s 2026 ‘Future of Healthcare Conference’ Returns to Irvine on October 7 at Major Inflection Point in U.S. Healthcare
28/09/2026
Dr. Sachin Jain of SCAN to keynote annual summit hosted at the UCI Beall Center for Innovation which will convene clinicians, policymakers, and community leaders to reimagine care across the lifespan IRVINE, Calif., [...]
Guerbet : H1 2026 Results.
28/09/2026
H1 2026 Results Revenue of €379.2m, nearly stable (-0.1%) at CER 1 and like-for-like 2 , in line with the Group’s forecast for the full year EBITDA of €30.6m, in line with the Group’s forecast for the full year Restated [...]
Guerbet : Résultats semestriels 2026.
28/09/2026
Résultats semestriels 2026 Chiffre d’affaires de 379,2 M€, quasiment stable (-0,1%) à TCC 1 et périmètre comparable 2 , en ligne avec les anticipations du Groupe sur l’ensemble de l’exercice EBITDA à 30,6 M€ en ligne [...]

Pages